In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Role of myocardial fibrosis in hypertrophic cardiomyopathy: A systematic review and updated meta-analysis of risk markers for sudden death

Session Poster Session 1

Speaker Marcelo Imbroinise Bittencourt

Congress : Heart Failure 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Hypertrophic Cardiomyopathy
  • Session type : Poster Session
  • FP Number : P517

Authors : MI Bittencourt (Rio de Janeiro,BR), SA Cader (Rio de Janeiro,BR), DV Araujo (Rio de Janeiro,BR), ALF Salles (Rio de Janeiro,BR), FN Albuquerque (Rio de Janeiro,BR), PPM Spineti (Rio de Janeiro,BR), DC Albuquerque (Rio de Janeiro,BR), R Mourilhe-Rocha (Rio de Janeiro,BR)

MI Bittencourt1 , SA Cader1 , DV Araujo1 , ALF Salles1 , FN Albuquerque1 , PPM Spineti1 , DC Albuquerque1 , R Mourilhe-Rocha1 , 1State University of Rio de Janeiro, Cardiology - Rio de Janeiro - Brazil ,


Background: Hypertrophic cardiomyopathy (HCM) is associated with sudden death (SD). Myocardial fibrosis is reportedly correlated with SD in these patients.
Purpose We performed a systematic review with meta-analysis, updating the risk markers (RMs) in HCM emphasizing myocardial fibrosis.
Methods: We reviewed HCM studies that addressed severe arrhythmic outcomes (SD, aborted SD, documented sustained ventricular tachycardia, or appropriate shock in patients with ICD) and the certain RMs: SD family history, severe ventricular hypertrophy, unexplained syncope, non-sustained ventricular tachycardia (NSVT) on 24-hour Holter monitoring, abnormal blood pressure response to exercise (ABPRE), and left ventricular outflow tract obstruction (LVOTO) in the MEDLINE, LILACS, and SciELO databases. We used relative risks (RRs) as an effect measure and random models for the analysis.
Results: Twenty-one studies were selected (14,901 patients aged 45 ± 16 years; men, 62.8%). Myocardial fibrosis was the major RM correlated with severe arrhythmic outcomes (RR, 3.43; 95% CI, 1.95-6.03). The other RMs, except for LVOTO, were also predictors: SD family history (RR, 1.75; 95% CI, 1.39-2.20), severe ventricular hypertrophy (RR, 1.86; 95% CI, 1.26-2.74), unexplained syncope (RR, 2.27; 95% CI, 1.69-3.07), NSVT (RR, 2.79; 95% CI, 2.29-3.41), and ABPRE (RR, 1.53; 95% CI, 1.12-2.08).
Conclusions: We confirmed the association of myocardial fibrosis and other RMs with severe arrhythmic outcomes in HCM and emphasize the need for new prediction models in managing these patients.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are